Cargando…
Antifungal Pipeline
In many ways, fungal diseases are forgotten or neglected. Given the significantly lower frequency compared to similar bacterial etiologies across the spectrum of infectious syndromes, it makes sense that anti-bacterial agents have seen the bulk of development in recent decades. The vast majority of...
Autores principales: | McCarty, Todd Patrick, Pappas, Peter G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450443/ https://www.ncbi.nlm.nih.gov/pubmed/34552887 http://dx.doi.org/10.3389/fcimb.2021.732223 |
Ejemplares similares
-
Editorial: Antifungal Pipeline: Build It Strong; Build It Better!
por: Perfect, John R., et al.
Publicado: (2022) -
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021) -
Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi
por: An, Lulu, et al.
Publicado: (2023) -
Antifungal Peptides as Therapeutic Agents
por: Fernández de Ullivarri, Miguel, et al.
Publicado: (2020) -
Potential of Gallium as an Antifungal Agent
por: Bastos, Rafael Wesley, et al.
Publicado: (2019)